new glp 1 agonist novo nordisk GLP-1 RA education Novo Nordisk promotes new GLP-1

GLP-1 stimulates insulin secretion, inhibits glucagon secretion at pancreatic cells and has also extrapancreatic influences as slowing of gastric emptying which increases the feeling of satiety

(2009) 296:E41521

Pancreatitis during treatment with liraglutide

Background Substance use disorder is a leading public health concern, affecting approximately 40 million people worldwide

Employment of the GLP-1RA liraglutide has been shown to diminish this damaging effect through upstream modulation of the PINK1/Parkin pathway to effectively counteract high glucose-induced cell dysfunction

Abstracts from the 2022 American Diabetes Association Meeting